FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.

BMC Cancer · 2014 · PMC3937056 · PMID 24499441

Europe PMC DOI

hedged sentences

0.1470

closest p · 2.9× alpha

0.1470

boldest claim

The sentences

showed a trendP = 0.147not close (p > 0.1)

The analysis showed a trend in favor of the LET + ZOL treatment (OR = 1.72; 95% CI, 0.827 to 3.586; P = 0.147).

also in 53,322 other papers

a positive trendno p-value reported

Discussion In this prematurely terminated, randomized phase II study in postmenopausal women with hormone receptor–positive primary breast cancer, a positive trend in the clinical tumor response was observed with the addition of zoledronic acid to neoadjuvant treatment with letrozole.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.